Skip to main content
Caplight Logo









NTxBio

NTxBio

Private
Rio Rancho, New MexicoHealthcare & Life Scienceshttps://ntxbio.com/

Last Round

Grant

May 14, 2025

Total Funding Raised

$77.32M

Company Overview

NTxBio is a biotechnology company that provides a cell-free biomanufacturing platform for the scalable production of high-quality RNA and protein therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clean Manufacturing

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

cell-free manufacturingmRNA synthesisbiomanufacturingprotein expressioncontinuous-flow manufacturingbiotech hardwarebenchtop bioreactorcell-free synthesisbioprocessingvaccine productionin vitro transcriptionIVTlab-on-a-chipbiotech platformsynthetic biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NTxBio Comparables

Compare NTxBio with similar companies based on industry and business-model similarity.

NTxBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tierra Biosciences
79%
Liberum Biotech
79%
Centillion Biosciences Inc.
76%

NTxBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 14, 2025
DebtDec 4, 2024
Series BNov 16, 2023
GrantFeb 25, 2020
Series AFeb 25, 2020

NTxBio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2025

    Opening a new $31 million facility and adding 170 jobs in Texas.

  • May 14, 2025

    $1.48M grant from Texas Enterprise Fund

Recent news

Latest coverage and updates

  • is_developingAug 19, 2026

    Ntxbio is developing innovative systems like NTxscribe and NTxpress.

  • launchesJul 7, 2026

    Ntxbio launched NTxscribe FLEX system on Jul 7th '26.

NTxBio Filings

Explore SEC and related filing metadata, where available.

NTxBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NTxBio's valuation, stock price, and market status.

Is NTxBio a public or private company?

NTxBio is a private company.

What is the current stock price of NTxBio?

NTxBio is a private company with no public stock price. No recent secondary market data is available.

How much is NTxBio worth (valuation)?

Valuation information for NTxBio is not publicly available.

Can I buy NTxBio stock?

NTxBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NTxBio's last funding round?

NTxBio's most recent funding round was Grant on May 14, 2025.

Who are the main investors in NTxBio?

Key investors in NTxBio include RA Capital Management, Anzu Partners, J.P. Morgan.

Will NTxBio IPO soon?

No public IPO plans have been announced for NTxBio.

How can I track NTxBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NTxBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersRio Rancho, New Mexico
Employee Range31
Year Founded2015
Last FundingMay 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?